TIM
ATRS

Total Investment Management’s Antares Pharma, Inc. ATRS Stock Holding History

Total Investment Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,400
Closed -$65K – 55
2018
Q3 		$65K Buy
+19,400
New +$59.9K 0.01% 48

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Total Investment Management's ATRS Position: Q4 2018 in Review

Total Investment Management sold out of Antares Pharma, Inc. (ATRS) in Q4 2018, closing a stake of 19,400 shares — an estimated $65K sold.

Total Investment Management first reported a position in ATRS in Q3 2018 and held it in 1 quarter. The position peaked at $65K in Q3 2018. 120 funds tracked by Wall St. Rank hold ATRS as of Q4 2018.

  • Total Investment Management reported no remaining Antares Pharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Total Investment Management sold 19,400 Antares Pharma, Inc. shares in Q4 2018, an estimated $65K.
  • Total Investment Management first reported a position in Antares Pharma, Inc. in Q3 2018 and held it in 1 quarter.
  • Total Investment Management's Antares Pharma, Inc. position peaked at $65K in Q3 2018.
  • 120 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2018.

Based on Total Investment Management's 13F filing for Q4 2018, filed 8 Feb 2019.